Shionogi files metreleptin in Japan on back of rare investigator-initiated trial
This article was originally published in Scrip
Executive Summary
Shionogi's recent submission for the approval of Amylin's metreleptin in Japan follows a rarely used local procedure for the clinical development of high-need drugs for niche indications.